MedWatch

Analysts: Stallergenes' approval may expand the market for allergy tablets

The fact that French company Stallergenes Greer can now also provide a tablet treatment for dust mite allergies in several European markets may ultimately benefit ALK, according to two analysts.

Photo: Stallergenes Greer/PR

Carnegie Investment Bank Equity Analyst Jesper Ilsøe notes that the US Food and Drug Administration approval of Stallergenes Greer's tablet for dust mite allergies may lead to a further expansion of the market for treating allergies with tablets, which is currently relatively small.

He expects that in the long term, Stallergenes will take over around 30 percent of the market for treating dust mite allergies with tablets. He further estimates that other vaccine companies like ALK can lean back and enjoy the increased competition.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs